https://www.selleckchem.com/pr....oducts/jak-inhibitor
Acute-on chronic liver failure (ACLF) occurs in hospitalised patients with cirrhosis and is characterised by multiorgan failures and high rates of short-term mortality. Without liver transplantation (LT), the 28-day mortality of patients with ACLF ranges between 18-25% in those with ACLF Grade 1 to 68-89% in those with ACLF Grade 3. It has become clear that there is lack of equity of access to LT for patients with ACLF across the world due to the current allocation policies, which are based on prognostic scores that underestimat